Dave opens the episode with gratitude during a difficult week, sharing how the OTP community’s support has helped him stay grounded after losing his 60,000-follower TikTok account overnight. He then breaks down major new data in obesity and diabetes medicine—including updates on Alzheimer’s trials, amicretin, tirzepatide, and orforglipron—emphasizing what these developments mean for patients and the future of personalized metabolic care.